Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban

Translated title of the contribution: Soluble syndecan-1 levels in different plasma cell dyscrasias

Judit Jánosi, A. Sebestyén, G. Mikala, Mónika Petö, János Jákó, Gyula Domján, Júlia Németh, Zoltán Kis, L. Kópper, István Vályi-Nagy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.

Original languageHungarian
Pages (from-to)165-168
Number of pages4
JournalOrvosi Hetilap
Volume146
Issue number4
Publication statusPublished - 2005

Fingerprint

Syndecan-1
Paraproteinemias
Syndecans
Serum
Multiple Myeloma
Plasma Cells
Monoclonal Gammopathy of Undetermined Significance
Drug Therapy
Plasmacytoma
Salmon
Proteoglycans
Bone Marrow Cells
Immunoglobulins
Reading
Cell Count
Bone Marrow
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jánosi, J., Sebestyén, A., Mikala, G., Petö, M., Jákó, J., Domján, G., ... Vályi-Nagy, I. (2005). Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban. Orvosi Hetilap, 146(4), 165-168.

Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban. / Jánosi, Judit; Sebestyén, A.; Mikala, G.; Petö, Mónika; Jákó, János; Domján, Gyula; Németh, Júlia; Kis, Zoltán; Kópper, L.; Vályi-Nagy, István.

In: Orvosi Hetilap, Vol. 146, No. 4, 2005, p. 165-168.

Research output: Contribution to journalArticle

Jánosi, J, Sebestyén, A, Mikala, G, Petö, M, Jákó, J, Domján, G, Németh, J, Kis, Z, Kópper, L & Vályi-Nagy, I 2005, 'Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban', Orvosi Hetilap, vol. 146, no. 4, pp. 165-168.
Jánosi, Judit ; Sebestyén, A. ; Mikala, G. ; Petö, Mónika ; Jákó, János ; Domján, Gyula ; Németh, Júlia ; Kis, Zoltán ; Kópper, L. ; Vályi-Nagy, István. / Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 4. pp. 165-168.
@article{2f5e14f1b3bc457fbc9258a4df51f9e5,
title = "Szol{\'u}bilis syndecan-1- (CD 138)-koncentr{\'a}ci{\'o} plazmasejt-dyscrasi{\'a}kban",
abstract = "Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.",
keywords = "Multiple myeloma, Prognostic marker, Syndecan-1",
author = "Judit J{\'a}nosi and A. Sebesty{\'e}n and G. Mikala and M{\'o}nika Pet{\"o} and J{\'a}nos J{\'a}k{\'o} and Gyula Domj{\'a}n and J{\'u}lia N{\'e}meth and Zolt{\'a}n Kis and L. K{\'o}pper and Istv{\'a}n V{\'a}lyi-Nagy",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "165--168",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban

AU - Jánosi, Judit

AU - Sebestyén, A.

AU - Mikala, G.

AU - Petö, Mónika

AU - Jákó, János

AU - Domján, Gyula

AU - Németh, Júlia

AU - Kis, Zoltán

AU - Kópper, L.

AU - Vályi-Nagy, István

PY - 2005

Y1 - 2005

N2 - Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.

AB - Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.

KW - Multiple myeloma

KW - Prognostic marker

KW - Syndecan-1

UR - http://www.scopus.com/inward/record.url?scp=15744388681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744388681&partnerID=8YFLogxK

M3 - Article

C2 - 15751511

AN - SCOPUS:15744388681

VL - 146

SP - 165

EP - 168

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 4

ER -